The influence of low (81 mg) versus high (325 mg) doses of ASA on the incidence of sirolimus-eluting stent thrombosis

Journal of Invasive Cardiology

Volumn 19, Issue 7, 2007, Pages 291-294

  Joyal, Dominique ^a   Freihage, Jeffrey H ^a   Cohoon, Kevin ^a   Tempelhof, Michael ^a   Leya, Ferdinand ^a   Dieter, Robert S ^a   Steen, Lowell ^a   Lewis, Bruce ^a   Arab, Dinesh ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; RAPAMYCIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; DRUG ELUTING STENT; DRUG MEGADOSE; FEMALE; HEART EJECTION FRACTION; HOSPITAL DISCHARGE; HOSPITAL MANAGEMENT; HUMAN; INTERNAL MAMMARY ARTERY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; RIGHT CORONARY ARTERY; ST SEGMENT ELEVATION; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CORONARY THROMBOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; RETROSPECTIVE STUDIES; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 34447256785     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:576S-99S.
2. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166-e286.
3. Peters RJG, Mehta SR, Fox KAA, et al for the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-1687.
4. Lefkovits J, Topol EJ. Role of platelet inhibitor agents in coronary artery disease. In: (Topol EJ, ed). Textbook of Interventional Cardiology. Elsevier Science: Philadelphia. 2003, pp. 3-32.
5. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978;61:314-319.
6. Majerus PW. Arachidonate metabolism in vascular disorders. J Clin Invest 1983;72:1521-1525.
7. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-1372.
8. Schwartz L, Bourassa M, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719.
9. Wallentin L. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991;18:1587-1593.
10. Collaboration, Antithrombotic Trialists. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br Med J 2002;324:71.
11. Fujii K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation. J Am Coll Cardiol 2005;45:995-998.
12. Lembo NJ, Black AJ, Roubin G, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;65:422.
13. Mufson L, Black A, Roubin G, et al. A randomized trial of aspirin in PTCA: Effect of high dose versus low dose aspirin on major complications and restenosis (Abstr). J Am Coll Cardiol 1988;11:236A.
14. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004:126:234S-264S.
15. Morice M-C, Serruys PW, Sousa JE, et al for the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773.
16. Moses JW, Leon MB, Popma JJ, et al for the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315.
17. Stone GW, Ellis SE, Cox DA, et al for the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221.
18. Lemos PA, Serruys PW, van Domburg R, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190.
19. Patrono C, Rodríguez LAG, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-2383.
20. Moreno R, Fernandez C, Hernandez R. Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-959.
21. Bavry AA, Kumbhani DJ, Helton T, et al. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention: A meta-analysis. J Am Coll Cardiol 2005;45:941-946.
22. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs. paclitaxel-eluting stents in patients with coronary artery disease: Meta-analysis of randomized trials. JAMA 2005;294:819-825.
23. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent trials. Circulation 2001;103:1967-1971.
24. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193.
25. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005;111;2257-2273.